Abstract: Triple-negative breast cancer is the most invasive and malignant type of breast cancer. At present, therapy for triple-negative breast cancer is the comprehensive treatment regimens based on chemotherapy, in which neoadjuvant chemotherapy plays an important role. However, nearly half of the patients with triple-negative breast cancer are resistant to the treatment, and the specific mechanism is still unclear. Single-cell sequencing is based on accurate assessment of a single cell of tumor, which can evaluate the changes of genome, transcriptome and epigenetic information of tumor in its occurrence and progression. It provides a powerful tool for the diagnosis of tumor subtypes, understanding the mechanism of drug resistance of tumor, finding new therapeutic targets and evaluating efficacy and prognosis, and has a wide application prospect in the neoadjuvant chemotherapy for triple-negative breast cancer.

Key words: Triple-negative breast cancer, Single-cell sequencing, Neoadjuvant chemotherapy, Tumor heterogeneity